Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein

Journal of Infectious Diseases

Volumn 201, Issue 3, 2010, Pages 473-477

  Baquir, Beverlie ^a   Lin, Lin ^a   Ibrahim, Ashraf S ^a,c   Fu, Yus ^a,c   Avanesian, Valentina ^a   Tu, Aug ^a   Edwards Jr , John ^a,c   Spellberg, Brad ^a,b,c  

^a Los Angeles Biomedical Research Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGAL PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 14; INTERLEUKIN 17; PROTEIN P70; PROTEIN RADLS3P N; UNCLASSIFIED DRUG; VACCINE; CYTOKINE; EPITOPE; FUNGUS ANTIBODY; FUNGUS VACCINE; IMMUNOGLOBULIN E;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; CYTOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; PRIORITY JOURNAL; BLOOD; CANDIDA; CANDIDIASIS; IMMUNOLOGY; METABOLISM;

ANTIBODIES, FUNGAL; CANDIDA; CANDIDIASIS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FUNGAL PROTEINS; FUNGAL VACCINES; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G;

EID: 75649102852     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/649901     Document Type: Article

References (17)

1. Spellberg B, Ibrahim AS, Lin L, et al. An antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis 2008; 197:957-971.
2. Spellberg B., Ibrahim AS, Yeaman M, et al. The anti-fungal rAls3p-N vaccine protects mice against the bacterium Staphylococcus aureus. In-fect Immun 2008; 76:4574-4580.
3. Lin L, Ibrahim AS, Xu X, et al. Thl-Thl7 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albi-cans infection in mice. PLoS Pathogens [in press].
4. Lin L, Ibrahim AS, Baquir B, Avanesian V, Fu Y, Spellberg B. Im-munological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol 2009; 55(3):293-295.
5. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008;47:401-409.
6. Hoyer LL, Payne TL, Bell M, Myers AM, Scherer S. Candida albicans ALS3 and insights into the nature of the ALS gene family. Curr Genet 1998;33:451-459.
7. 7. Lin L, Ibrahim AS, Avanesian V, et al. Vaccine immunogenicity and efficacy vary considerably by diluent used for aluminum hydroxide adjuvant. Clin Vaccine Immunol 2008; 15:582-584. (Pubitemid 351967086)
8. 8. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317. (Pubitemid 39050477)
9. 9. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epide- miology, diagnosis, and treatment. Med Mycol 2007;45:321-346. (Pubitemid 46839802)
10. Peter CG. Responses of children immunized with capsular polysac-charide of Hemophilus influenzae type b, by David H. Smith, MD, et al, Pediatrics, 1973; 52:637-644 and
11. Haemophilus influenzae type b cap-sular polysaccharide vaccine in children: a double-blind field study of 100 000 vaccinees 3 months to 5 years of age in Finland, by Heikki Peltola, MD et al, Pediatrics, 1977;60:730-737.
12. Pediatrics 1998; 102: 252-254.
13. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009; 30:189-209.
14. Gray BM, Dillon HC Jr. Epidemiological studies of Streptococcus pneumo-niae in infants: antibody to types 3, 6, 14, and 23 in the first two years of life. J Infect Dis 1988; 158:948-955.
15. Lifshitz S, Dagan R, Shani-Sekler M, et al. Age-dependent preference in human antibody responses to Streptococcus pneumoniae polypeptide antigens. Clin Exp Immunol 2002; 127:344-353.
16. Eskola J, Kayhty H, Takala AK, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young chil-dren against invasive Haemophilus influenzae type b disease. N Engl J Med 1990;323:1381-1387.
17. Musher DM, Groover JE, Rowland JM, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae, prevalence, persistence, and response to revaccination. Clin Infect Dis 1993; 17:66-73.